Jeffery S. Carter

3.1k total citations · 1 hit paper
7 papers, 997 citations indexed

About

Jeffery S. Carter is a scholar working on Organic Chemistry, Pharmacology and Molecular Biology. According to data from OpenAlex, Jeffery S. Carter has authored 7 papers receiving a total of 997 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Organic Chemistry, 5 papers in Pharmacology and 1 paper in Molecular Biology. Recurrent topics in Jeffery S. Carter's work include Inflammatory mediators and NSAID effects (5 papers), Synthesis and biological activity (3 papers) and Synthesis and Reactions of Organic Compounds (2 papers). Jeffery S. Carter is often cited by papers focused on Inflammatory mediators and NSAID effects (5 papers), Synthesis and biological activity (3 papers) and Synthesis and Reactions of Organic Compounds (2 papers). Jeffery S. Carter collaborates with scholars based in United States. Jeffery S. Carter's co-authors include Karen Seibert, John J. Talley, Carol M. Koboldt, Matthew J. Graneto, David Brown, Ben S. Zweifel, Jaime L. Masferrer, William E. Perkins, Roland S. Rogers and Alexander F. Shaffer and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry and Medicinal Research Reviews.

In The Last Decade

Jeffery S. Carter

7 papers receiving 938 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2

2000 569 citations John J. Talley, David Brown et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Jeffery S. Carter

Since Specialization

Citations

This map shows the geographic impact of Jeffery S. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffery S. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffery S. Carter more than expected).

Fields of papers citing papers by Jeffery S. Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffery S. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffery S. Carter. The network helps show where Jeffery S. Carter may publish in the future.

Co-authorship network of co-authors of Jeffery S. Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffery S. Carter. A scholar is included among the top collaborators of Jeffery S. Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffery S. Carter. Jeffery S. Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2 breakdown → 2000 ·Journal of Medicinal Chemistry ·John J. Talley, David Brown, Jeffery S. Carter, Matthew J. Graneto, Carol M. Koboldt, Jaime L. Masferrer, William E. Perkins, Roland S. Rogers, Alexander F. Shaffer, (unknown), Ben S. Zweifel, Karen Seibert	569
2	N-[[(5-Methyl-3-phenylisoxazol-4-yl)- phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration 2000 ·Journal of Medicinal Chemistry ·John J. Talley, Stephen R. Bertenshaw, David Brown, Jeffery S. Carter, Matthew J. Graneto, Michael S. Kellogg, Carol M. Koboldt, Jinhua Yuan, (unknown), Karen Seibert	172
3	4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2) 1999 ·Medicinal Research Reviews ·John J. Talley, Stephen R. Bertenshaw, David Brown, Jeffery S. Carter, (unknown), Carol M. Koboldt, Jaime L. Masferrer, Bryan H. Norman, D. Joseph Rogier, Ben S. Zweifel, Karen Seibert	32
4	Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors 1999 ·Bioorganic & Medicinal Chemistry Letters ·Jeffery S. Carter, D. Joseph Rogier, Matthew J. Graneto, Karen Seibert, Carol M. Koboldt, Yan Zhang, John J. Talley	28
5	Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors 1999 ·Bioorganic & Medicinal Chemistry Letters ·Jeffery S. Carter, Steven W. Kramer, John J. Talley, Thomas D. Penning, Paul W. Collins, Matthew J. Graneto, Karen Seibert, Carol M. Koboldt, Jaime L. Masferrer, Ben S. Zweifel	145
6	Effect of Phosphoramidon (Endothelin Converting Enzyme Inhibitor) and BQ-123 (Endothelin Receptor Subtype A Antagonist) on Blood Pressure in Hypertensive Rats 1993 ·American Journal of Hypertension ·Ellen G. McMahon, Maria A. Palomo, (unknown), Stephen R. Bertenshaw, Jeffery S. Carter	37
7	Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as .gamma.-turn templates 1989 ·The Journal of Organic Chemistry ·Daniel S. Kemp, Jeffery S. Carter	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact